IMCR (Immunocore Holdings) Change In Payables And Accrued Expense : $54.3 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings Change In Payables And Accrued Expense?

Immunocore Holdings's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was $-7.6 Mil. It means Immunocore Holdings's Accounts Payable & Accrued Expense declined by $7.6 Mil from Dec. 2024 to Mar. 2025 .

Immunocore Holdings's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was $78.8 Mil. It means Immunocore Holdings's Accounts Payable & Accrued Expense increased by $78.8 Mil from Dec. 2023 to Dec. 2024 .

Immunocore Holdings Change In Payables And Accrued Expense Historical Data

The historical data trend for Immunocore Holdings's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings Change In Payables And Accrued Expense Chart

Immunocore Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-5.14

12.16

46.67

41.71

78.77

Immunocore Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															16.85	31.35	25.92	4.66	-7.60

Immunocore Holdings Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $54.3 Mil.

Immunocore Holdings Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Immunocore Holdings's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunocore Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (NAS:IMCR) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

6YG:Germany

Address

92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.immunocore.com

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.